Core Insights - Chart Industries leverages expertise in cryogenic and heat transfer technologies to support energy transition initiatives and industrial efficiency, positioning itself as a key partner in rapidly evolving markets [1] Financial Performance - The company generates revenue through capital equipment sales, process technology, aftermarket services, and equipment leasing, with a diversified offering across four business segments [2] - As of the latest report, Chart Industries shares were priced at $205.85, reflecting a 5% increase over the past year, underperforming the S&P 500, which rose approximately 15% in the same period [2] Investment Activity - Absolute Gestao de Investimentos disclosed a new position in Chart Industries, acquiring 440,746 shares valued at $88.22 million as of September 30, indicating significant investment interest [3] - The fund's allocation of roughly 11% of its reported U.S. equity assets to Chart Industries signals strong conviction in the company's fundamentals [4] Operational Highlights - In the third quarter, Chart Industries experienced a nearly 44% year-over-year increase in orders, reaching a record $1.68 billion, with total backlog exceeding $6 billion [5] - Demand is driven by sectors such as LNG, data centers, hydrogen, carbon capture, and industrial gas, with customers committing capital years in advance [5] - Despite GAAP losses related to merger and termination costs, adjusted operating margins improved to approximately 23%, indicating strong underlying earnings potential [5] Strategic Fit - The investment in Chart Industries aligns with broader themes of global growth and emerging markets, as the company's equipment addresses energy security, electrification, and decarbonization [6]

Core Insights - STERIS plc (STE) is set to announce its first-quarter fiscal 2026 results on August 7, with previous quarter adjusted EPS of $2.74, exceeding Zacks Consensus Estimate by 5.79% [1] - The Zacks Consensus Estimate for revenues is $1.36 billion, reflecting a 6.2% increase year-over-year, while EPS is estimated at $2.32, indicating a 14.3% year-over-year growth [2] Revenue Estimates - Healthcare segment is expected to show robust growth driven by increased procedure volumes in the U.S. and gains in pricing and market share [4] - Healthcare capital equipment order growth is anticipated to remain strong despite shipment issues, with projected revenue growth of 5.1% year-over-year [5] - Applied Sterilization Technologies (AST) segment is expected to see organic revenue growth, with revenues likely increasing by 6.3% year-over-year [6][7] Life Sciences Segment - Life Sciences segment revenues may rise by 5.5% year-over-year, supported by favorable mix, pricing, and divestiture, despite a decline in capital equipment revenue [8][9] Earnings Expectations - STERIS has an Earnings ESP of -3.24%, indicating a lower likelihood of beating earnings estimates this quarter [10] - The company currently holds a Zacks Rank of 3, suggesting a hold position [10]